Antech's in-clinic version of the Nu.Q Canine Cancer Test operates on the Element i+ Analyzer, providing veterinarians with a rapid, accurate and cost-effective cancer screening tool for high-risk breeds and older dogs, at the patient side, with results in about six minutes
Element i+ Analyzer. (Credit: PRNewsfoto/ VolitionRx Limited)
VolitionRx Limited, a multi-national epigenetics company, has announced that its Nu.Q Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
Antech’s in-clinic version of the Nu.Q Canine Cancer Test operates on the Element i+ Analyzer, providing veterinarians with a rapid, accurate and cost-effective cancer screening tool for high-risk breeds and older dogs, at the patient side, with results in about six minutes.
Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “Through this collaboration, our groundbreaking Nu.Q® technology is now available to veterinarians across the U.S. and Europe, enabling vital canine cancer screening and providing in-clinic results within minutes. By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer¹ earlier and help pet owners make timely, informed decisions about cancer care.”
Dr Butera added:
“Antech’s rollout of the Nu.Q® Canine Cancer Test marks a huge step forward for Volition as we seek to fulfil our mission of ensuring our epigenetic technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes.”
Volition’s original license and supply agreement was between Belgian Volition SRL and Heska, an Antech company, part of Mars Science & Diagnostics.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis.
Source: Company Press Release